Department of Surgery, Boston Medical Center, Boston University School of Medical, Boston, MA, USA.
Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ann Surg Oncol. 2022 Dec;29(13):8424-8431. doi: 10.1245/s10434-022-12360-z. Epub 2022 Sep 4.
Routine screening plays a critical role in the diagnosis of hepatocellular carcinoma (HCC), but not all patients undergo consistent surveillance. This study aims to evaluate surveillance patterns and their association with diagnosis stage and survival among Medicare patients at risk for HCC.
Patients with HCC and guideline-based screening eligibility who underwent imaging with ultrasound or abdominal magnetic resonance imaging (MRI) in the 2 years prior to diagnosis were identified from SEER-Medicare (2008-2015). Three surveillance cohorts were created: diagnostic (imaging only within 3 months prior), intermittent (imaging only once within 2 years prior, excluding diagnostic), and routine (at least two imaging encounters within 2 years prior, excluding diagnostic). Multivariable logistic regression was used to predict early-stage diagnosis (stage I-II), and 5-year survival was evaluated using the accelerated failure time method with Weibull distribution.
Among 2261 eligible patients, 26.1% were classified as diagnostic, 15.8% as intermittent, and 58.1% as routine surveillance. The median age was 74 years (IQR 70-78 years). The majority of patients had a preexisting cirrhosis diagnosis (81.5%). Routine and intermittent, compared with diagnostic, surveillance were predictive of early-stage disease (routine: OR 2.05, 95% CI 1.64-2.56; intermittent: OR 1.43, 95% CI 1.07-1.90). Patients who underwent routine surveillance had significantly lower risk of mortality (HR 0.84, 95% CI 0.75-0.94) compared with the diagnostic group.
A large proportion of screening-eligible patients do not undergo routine surveillance, which is associated with late-stage diagnosis and higher risk of mortality. These findings demonstrate the impact of timely and consistent healthcare access and can guide interventions for promoting surveillance among these patients.
常规筛查在肝细胞癌(HCC)的诊断中起着至关重要的作用,但并非所有患者都进行了一致的监测。本研究旨在评估监测模式及其与医疗保险 HCC 高危患者诊断分期和生存的关系。
从 SEER-Medicare(2008-2015 年)中确定了在诊断前 2 年内接受超声或腹部磁共振成像(MRI)检查且符合指南筛查标准的 HCC 患者。创建了三个监测队列:诊断性(仅在诊断前 3 个月内进行影像学检查)、间歇性(仅在 2 年内进行一次影像学检查,不包括诊断性)和常规性(在 2 年内至少进行两次影像学检查,不包括诊断性)。多变量逻辑回归用于预测早期诊断(I 期-II 期),使用 Weibull 分布的加速失效时间法评估 5 年生存率。
在 2261 名符合条件的患者中,26.1%被归类为诊断性,15.8%为间歇性,58.1%为常规监测。中位年龄为 74 岁(IQR 70-78 岁)。大多数患者有预先存在的肝硬化诊断(81.5%)。与诊断性监测相比,常规性和间歇性监测更能预测早期疾病(常规性:OR 2.05,95%CI 1.64-2.56;间歇性:OR 1.43,95%CI 1.07-1.90)。与诊断组相比,接受常规监测的患者死亡率风险显著降低(HR 0.84,95%CI 0.75-0.94)。
很大一部分符合筛查标准的患者没有进行常规监测,这与晚期诊断和更高的死亡率有关。这些发现表明了及时和一致的医疗保健获得的影响,并可以为这些患者的监测提供指导干预。